124 related articles for article (PubMed ID: 32460977)
21. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.
Zhang H; Wilmot B; Bottomly D; Dao KT; Stevens E; Eide CA; Khanna V; Rofelty A; Savage S; Reister Schultz A; Long N; White L; Carlos A; Henson R; Lin C; Searles R; Collins RH; DeAngelo DJ; Deininger MW; Dunn T; Hein T; Luskin MR; Medeiros BC; Oh ST; Pollyea DA; Steensma DP; Stone RM; Druker BJ; McWeeney SK; Maxson JE; Gotlib JR; Tyner JW
Blood; 2019 Sep; 134(11):867-879. PubMed ID: 31366621
[TBL] [Abstract][Full Text] [Related]
22. [Study of a patient with Myelodysplastic/myeloproliferative neoplasm with co-morbid neutrophilia and a novel NCOR1::GLYR1 fusion gene].
Lei Y; Zhao X; Zhao H; Cheng Y; Wang S; Li J; Zhu Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2024 Apr; 41(4):404-410. PubMed ID: 38565504
[TBL] [Abstract][Full Text] [Related]
23. Neutrophilic panniculitis associated with myelodysplastic syndrome/myeloproliferative neoplasm: a case report and literature review.
Cohen AJ; Gleason LK; Bhatti SA; Nikbakht N
Int J Dermatol Venereol; 2023 Sep; 6(3):168-171. PubMed ID: 37811487
[TBL] [Abstract][Full Text] [Related]
24. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes - Advances in treatment.
McCullough KB; Patnaik MM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101130. PubMed ID: 32460984
[TBL] [Abstract][Full Text] [Related]
25. Molecular genetics of MDS/MPN overlap syndromes.
Hunter AM; Padron E
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101195. PubMed ID: 33038984
[TBL] [Abstract][Full Text] [Related]
26. The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?
Milunović V; Mišura Jakobac K; Mandac Rogulj I; Martinović M; Radić-Krišto D; Ostojić Kolonić S
Expert Rev Hematol; 2020 Jul; 13(7):771-779. PubMed ID: 32579408
[TBL] [Abstract][Full Text] [Related]
27. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM; Lasho T
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
[TBL] [Abstract][Full Text] [Related]
28. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
[TBL] [Abstract][Full Text] [Related]
29. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM; Tefferi A
Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
[TBL] [Abstract][Full Text] [Related]
31. Targeting the Microenvironment in MDS: The Final Frontier.
Teodorescu P; Pasca S; Dima D; Tomuleasa C; Ghiaur G
Front Pharmacol; 2020; 11():1044. PubMed ID: 32742264
[TBL] [Abstract][Full Text] [Related]
32. MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment.
Grabek J; Straube J; Bywater M; Lane SW
Cells; 2020 Aug; 9(8):. PubMed ID: 32823933
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre.
Deschamps P; Moonim M; Radia D; Curto-Garcia N; Woodley C; Bassiony S; O'Sullivan J; Harrington P; Raj K; Francis Y; Kordasti S; Ali S; Harrison CN; McLornan DP
Br J Haematol; 2021 May; 193(4):792-797. PubMed ID: 33751548
[TBL] [Abstract][Full Text] [Related]
34. Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.
Wan Z; Han B
Front Oncol; 2020; 10():579221. PubMed ID: 33117717
[TBL] [Abstract][Full Text] [Related]
35. Atypical Chronic Myeloid Leukemia: Where Are We Now?
Crisà E; Nicolosi M; Ferri V; Favini C; Gaidano G; Patriarca A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962122
[TBL] [Abstract][Full Text] [Related]
36. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.
Estey E; Hasserjian RP; Döhner H
Blood; 2022 Jan; 139(3):323-332. PubMed ID: 34111285
[TBL] [Abstract][Full Text] [Related]
37. Congenital disorders of platelet function: disorders of signal transduction and secretion.
Rao AK
Am J Med Sci; 1998 Aug; 316(2):69-76. PubMed ID: 9704660
[TBL] [Abstract][Full Text] [Related]
38. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
39. The MPL mutation.
Guglielmelli P; Calabresi L
Int Rev Cell Mol Biol; 2021; 365():163-178. PubMed ID: 34756243
[TBL] [Abstract][Full Text] [Related]
40. Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).
Bewersdorf JP; Zeidan AM
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33807279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
